Spherix granted exclusive option to license G4-1 from University of Kentucky
Spherix Incorporated announced that the Company has executed an exclusive option agreement with the University of Kentucky related to its anticancer drug designated G4-1, a novel proteasome inhibitor. Spherix's Option includes two issued patents, United States Patent Nos. 9,493,439 and 9,586,946, each having expiration dates in the mid-2030's. The lead inventors for both patents are Chang-Guo Zhan, professor, and Kyung Bo Kim, associate professor, in UK's College of Pharmacy. Under the Option, Spherix has until late November to complete its due diligence and execute a license agreement. A report of G4-1's anticancer effects has been published in Miller et al., Proteasome Inhibitors with Pyrazole Scaffolds from Structure-Based Virtual Screening, J. Med. Chem. 58:2036-2041. According to the Miller Article: G4-1 is highly effective in mice in suppressing tumor growth in a mouse xenograft model of prostate cancer. It demonstrates excellent metabolic stability profiles in mouse and human liver microsomes, as compared with two other FDA-approved proteasome inhibitors, bortezomib and carfilzomib, which are known to undergo rapid metabolic inactivation. It was identified from ~340,000 small molecule candidates against the active site of proteosomes. It was highly effective in suppressing solid tumor growth in vivo, a utility that the FDA Approved Drugs lack, as clearly demonstrated by multiple clinical trials. Its anticancer effect was not negatively impacted in cancer cell line models by acquired resistance to the FDA Approved Drugs. It exhibited no apparent systemic toxicity in the xenograft mouse model.